A study from Apyx Medical, the maker of the Renuvion device, found that patients who received the treatment alongside liposuction reported improved satisfaction compared to those who had liposuction alone, according to reporting by Investing.com and Stock Titan.
Apyx Medical trades on the Nasdaq stock exchange under the ticker APYX. Renuvion is the company's primary commercial product, a device used in body contouring procedures that is applied during or after liposuction to address skin laxity, a common concern among patients who undergo fat removal.
The study results were released publicly and reported across financial and medical news outlets on May 14, 2026. The findings indicate that adding Renuvion to a liposuction procedure produced measurably higher satisfaction scores among patients, though the specific metrics and study size were not detailed in the summaries available from the reporting outlets.
Patient satisfaction is a key commercial and clinical benchmark for cosmetic procedure devices, and positive study results can influence both physician adoption rates and payer coverage decisions. Apyx Medical has been working to expand clinical evidence supporting broader use of Renuvion across body contouring applications.
The company has not yet announced peer-reviewed publication details for this specific study based on the available reporting.
